Analyst Ratings For Akcea Therapeutics (NASDAQ:AKCA)
Today, BMO Capital Markets raised its price target on Akcea Therapeutics (NASDAQ:AKCA) to per share.
Some recent analyst ratings include
- 2/27/2018-Stifel Nicolaus was Downgraded by analysts at Stifel Nicolaus from a “Buy ” rating to a ” Hold” rating. They now have a $20.00 price target on the stock.
- 2/27/2018-Cowen was Downgraded by analysts at Cowen from a “Outperform ” rating to a ” Market Perform” rating.
- 2/27/2018-Wells Fargo & Co was Downgraded by analysts at Wells Fargo & Co from a “Outperform ” rating to a ” Market Perform” rating. They now have a $27.00 price target on the stock.
- On 7/19/2017 Ionis Pharmaceuticals Inc, Major Shareholder, bought 3,125,000 with an average share price of $8.00 per share and the total transaction amounting to $25,000,000.00.
Recent Trading Activity for Akcea Therapeutics (NASDAQ:AKCA)
Shares of Akcea Therapeutics closed the previous trading session at 17.66 down -4.91 21.77% with 16.559999465942383 shares trading hands.